Clinical Trial

A Study of HS-20089 in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 3, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
HS-20089 is a novel DAR-6 antibody-drug conjugate （ADC） targeting B7-H4. In preclinical studies, it inhibited tumor cell growth expressing B7-H4 in vitro and in vivo. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-20089 in Patients With Advanced Solid Tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-02-21; most recent amendment 2024-04-01.
Trial Details
NCT Number NCT05263479
Lead Sponsor Shanghai Hansoh Biomedical Co., Ltd
Conditions Advanced Solid Tumor
Enrollment 177 participants
Start Date 2022-01-05
Primary Completion 2024-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-03